Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Brian B. Hansen sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $62.97, for a total transaction of $944,550.00. Following the sale, the executive vice president now owns 17,991 shares in the company, valued at $1,132,893.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Tandem Diabetes Care stock traded up $1.53 during mid-day trading on Tuesday, hitting $63.44. The company had a trading volume of 953,121 shares, compared to its average volume of 1,744,785. The stock has a market cap of $3.75 billion, a PE ratio of -24.88 and a beta of 0.33. Tandem Diabetes Care Inc has a 1 year low of $26.40 and a 1 year high of $74.81. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.21 and a current ratio of 2.53. The business has a fifty day moving average of $63.77.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.20. The company had revenue of $93.26 million for the quarter, compared to analyst estimates of $69.95 million. Tandem Diabetes Care had a negative net margin of 19.55% and a negative return on equity of 19.31%. The firm’s revenue was up 173.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.33) earnings per share. As a group, equities analysts expect that Tandem Diabetes Care Inc will post -0.65 EPS for the current year.

A number of analysts recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of Tandem Diabetes Care from $58.00 to $70.00 and gave the stock a “hold” rating in a research note on Wednesday, May 1st. BidaskClub upgraded shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 23rd. Lake Street Capital restated a “buy” rating on shares of Tandem Diabetes Care in a research note on Monday, June 17th. Oppenheimer upped their target price on shares of Tandem Diabetes Care from $80.00 to $84.00 in a research note on Friday, August 2nd. Finally, Svb Leerink began coverage on shares of Tandem Diabetes Care in a research note on Monday, May 13th. They issued an “outperform” rating and a $83.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $68.38.

Hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in shares of Tandem Diabetes Care by 53.3% in the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 160 shares during the period. Bremer Bank National Association acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at approximately $31,000. TRUE Private Wealth Advisors acquired a new stake in shares of Tandem Diabetes Care in the second quarter valued at approximately $33,000. James Investment Research Inc. boosted its holdings in shares of Tandem Diabetes Care by 15.9% in the second quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after acquiring an additional 180 shares during the period. Finally, Stephens Inc. AR acquired a new stake in shares of Tandem Diabetes Care in the second quarter valued at approximately $113,000. 79.75% of the stock is owned by institutional investors and hedge funds.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Story: Why is a lock-up period needed for an IPO?

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.